Core Viewpoint - Political uncertainty has created buying opportunities among blue-chip healthcare stocks with significant dividends, particularly due to the nomination of Robert F. Kennedy Jr. as Secretary of Health and Human Services, which has introduced volatility in the healthcare sector [1][2]. Group 1: AbbVie - AbbVie shares are down over 18% from their high, influenced by political factors and the $8.7 billion acquisition of Cerevel, which faced setbacks with its schizophrenia drug emraclidine failing clinical trials [3][4]. - Despite the challenges, AbbVie remains a well-diversified company with a solid dividend yield of 3.7% and a payout ratio of 56% of estimated 2024 earnings, indicating financial stability [4][5]. - The stock trades at a forward P/E ratio of 15, with analysts projecting earnings growth of 8% to 9% annually, presenting an opportunity for investors to achieve total returns averaging 11% to 13% annually [5]. Group 2: Pfizer - Pfizer's stock has been negatively impacted by declining earnings and industry sentiment, trading at less than 9 times earnings, with a dividend yield of 6.7%, the highest since the financial crisis [6][7]. - The company's dividend payout ratio is only 58% of its 2024 earnings estimates, and Pfizer is shifting focus to oncology, with expected earnings growth of 10% to 11% annually over the next three to five years [7][8]. - Pfizer presents a high-yield dividend stock at a bargain price, with management committed to supporting and increasing the dividend, making it a contrarian investment opportunity [8]. Group 3: Johnson & Johnson - Johnson & Johnson's stock has declined 18% from its high, trading at 15 times 2024 earnings estimates, amid ongoing talcum powder litigation that could incur significant costs [9][10]. - The company maintains strong fundamentals with over $20 billion in cash, and any settlements are expected to be paid over many years, indicating resilience [10][11]. - Analysts forecast earnings growth of 5% to 6% annually, with a modest 50% payout ratio based on 2024 earnings estimates, providing a generous 3.2% yield and a growing dividend [11].

As I was researching this article about AbbVie (NYSE: ABBV ), its price fell 16.8% due to negative data from two Phase 2 clinical trials evaluating the efficacy of emraclidine in treating schizophrenia. The stock fell in five consecutive sessions beforeWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs ...

Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie (ABBV -1.23%) is no exception. Nonetheless, the next five years will likely see it growing faster than the last five years, and shareholders are apt to benefit.Here's where this company will be going, and where it's probably going to end up.It's hard to see this business getting any smallerIn the next five years, expect AbbVie to continue to compete in the disease areas t ...

AbbVie (ABBV) announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer.The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatments.Following the approval, Elahere became the first and only FRα-directe ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .Analyst’s Disclosure: I/we have a beneficial long position in the shares of PEP, LMT, NOC, ABBV, UNP, ODFL, LHX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (o ...

ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer ELAHERE represents the first treatment to demonstrate an overall survival benefit in a Phase 3 trial in platinum-resistant ovarian cancer compared with chemotherapy VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the companion diagnostic to identify ovarian cancer patients eligible for ELAHERE, also receives CE MarkNORTH CHICAGO, Ill., Nov. ...

AbbVie’s (ABBV) stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily oral candidate for treating schizophrenia, failed to meet their primary endpoints. Emraclidine was added to AbbVie’s pipeline with this year’s acquisition of Cerevel and was a key reason for AbbVie to buy the company, thus bringing into question the viability of the deal.The failure of the phase II s ...

The drugmaker has convincingly laid to rest the biggest threat to its top line.It's always a good sign when a company successfully navigates a period of uncertainty with the help of a well-executed plan. For AbbVie, (ABBV -0.42%) it looks like some celebration is in order, because it just resolved one of its most pressing issues of the past few years.Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today.A major period of uncertainty is endingAt the start o ...

These companies have solid businesses and excellent dividend growth track records.The healthcare sector might not be at the forefront of exciting developments like artificial intelligence, but because good medical care is always in high demand, many healthcare companies boast stable, reliable businesses. That's precisely the kind that can also sustain growing dividends, making the industry pretty attractive for income-oriented investors.Which healthcare stock can dividend investors safely buy? Let's conside ...

AbbVie Migraine Career Catalyst Award™ contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in migraine treatment, is committed to addressing the impact of migraine in the workplace Nearly 40 million Americans are living with migraine, a debilitating neurological disease, and are more likely to call in sick due to symptoms associated with migraine.1-2NORTH CHICAGO, Ill., Nov. 14, 2024 /PRNewswire/ -- AbbVie ...